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A population pharmacokinetics analysis was performed after intravenous ganciclovir and oral valganciclovir
in solid organ transplant patients with cytomegalovirus. Patients received ganciclovir at 5 mg/kg of body weight
(5 days) and then 900 mg of valganciclovir (16 days), both twice daily with dose adjustment for renal function.
A total of 382 serum concentrations from days 5 and 15 were analyzed with NONMEM VI. Renal function given
by creatinine clearance (CLCR) was the most influential covariate in CL. The final pharmacokinetic parameters
were as follows: ganciclovir clearance (CL) was 7.49  (CLCR/57) liter/h (57 was the mean population value of
CLCR); the central and peripheral distribution volumes were 31.9 liters and 32.0 liters, respectively; intercom-
partmental clearance was 10.2 liter/h; the first-order absorption rate constant was 0.895 h1; bioavailability
was 0.825; and lag time was 0.382 h. The CLCR was the best predictor of CL, making dose adjustment by this
covariate important to achieve the most efficacious ganciclovir exposure.
Cytomegalovirus (CMV), the most common opportunistic
pathogen affecting solid organ transplant (SOT) patients (24),
is associated with significant morbidity and mortality (25). In-
travenous (i.v.) ganciclovir has been the gold standard for both
prevention and treatment of CMV disease in SOT patients
(20). The risk of neutropenia, the need for catheter access, and
the costs and inconvenience of patient hospitalization after i.v.
ganciclovir use have led to the development of oral formula-
tions. Oral ganciclovir is effective in preventing CMV infection
and disease, but its low bioavailability (F) limits the degree of
viral suppression and may lead to the emergence of viral re-
sistance (6, 18). The development of valganciclovir, an orally
available ester prodrug of ganciclovir, has overcome the low F
of ganciclovir (7). Following oral intake, the majority of val-
ganciclovir is rapidly converted to ganciclovir by intestinal and
hepatic esterases. Ganciclovir is entirely cleared by renal ex-
cretion (7).
The efficacy and safety of oral valganciclovir (900 mg) for the
treatment of CMV disease in SOT patients have been shown to
be comparable to the efficacy and safety of i.v. ganciclovir (5
mg/kg of body weight) when both drugs were given twice daily
for 21 days and followed by 900 mg of valganciclovir daily for
28 days (1, 2).
The pharmacokinetics of ganciclovir after i.v. ganciclovir
and/or oral valganciclovir administration have been studied in
different patient populations (4, 8, 11, 28, 29). Some authors
(21) have demonstrated equivalence between different single
doses of oral ganciclovir and valganciclovir and i.v. ganciclovir
using noncompartmental pharmacokinetic analysis. However,
this approach cannot provide a clinically applicable model for
dose adjustment. Such a model would be very useful to achieve
the required ganciclovir exposure to ensure efficacy and avoid
hematological adverse events and/or CMV resistance. It could
be the prerequisite step for characterization of the relationship
between ganciclovir exposure and viral eradication. In a pre-
vious study of SOT recipients with donor-positive/recipient-
negative CMV serostatus (27), viremia was suppressed during
prophylaxis with ganciclovir exposure values of 40 to 50
g  hr/ml and there was only a weak tendency to increased
neutropenia and leukopenia with higher ganciclovir exposure.
Therefore, dose adjustment could be based on this exposure
value. Yuen et al. (29) have described the population pharma-
cokinetics of ganciclovir in kidney transplant and human im-
munodeficiency virus (HIV)-positive patients. Wiltshire et al.
(26) also described the population pharmacokinetics of oral
ganciclovir compared with those of valganciclovir in SOT pa-
tients. However, population studies dealing with pharmacoki-
netics of ganciclovir after i.v. ganciclovir followed by oral val-
ganciclovir in SOT patients infected by CMV where drug
disposition and F could be estimated are lacking.
The aims of this study were (i) to establish the population
pharmacokinetics of ganciclovir after i.v. ganciclovir fol-
lowed by oral valganciclovir in SOT patients infected by
CMV; (ii) to evaluate the effects of several physiopatholog-
ical factors on the disposition kinetics of ganciclovir and to
find potential predictive factors for dosage individualiza-
tion; and (iii) to evaluate the effectiveness of the manufac-
turer’s recommended adjusted dose in preventing under- or
overexposure in SOT patients.
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MATERIALS AND METHODS
Study design. A prospective clinical trial performed according to good clinical
practice and in accordance with the Declaration of Helsinki was carried out at the
Hospital Universitari de Bellvitge, Barcelona, Spain, between March 2004 and Feb-
ruary 2006. All patients provided written informed consent (clinicaltrials.gov iden-
tifier NCT00730769).
Patients with established CMV infection undergoing allogeneic SOT (kidney,
liver, or heart) were eligible for inclusion if they were 18 years old and pre-
sented with positive CMV antigenemia (pp65) defined as 20 positive cells/105
peripheral blood mononuclear cells. Patients with severe CMV tissue-invasive
disease, absolute neutrophil counts of 500/mm3, platelet counts of 25,000/
mm3, hemoglobin at 80 g/liter, or estimated glomerular filtration rates of 10
ml/min (according to the Cockroft-Gault formula [9]) were excluded. Demo-
graphic characteristics such as age, gender, weight, transplant type, clinical lab-
oratory measurements (creatinine [CR] and CR clearance [CLCR] estimated
according to the Cockcroft-Gault formula [5]), and concomitant immunosup-
pressive medication were recorded.
Ganciclovir/valganciclovir administration. Patients received i.v. ganciclovir
(Cymevene; F. Hoffmann-La Roche Ltd., Basel, Switzerland) at 5 mg/kg over 1 h
twice daily for 5 days followed by 900 mg of oral valganciclovir (Valcyte; F.
Hoffmann-La Roche Ltd., Basel, Switzerland) twice daily for 16 days (21 days of
treatment). For patients with impaired renal function, i.v. and oral doses were
adjusted by CLCR (Cockcroft-Gault formula [5]) in accordance with the manu-
facturer’s recommendations (Table 1).
Blood sampling and drug analysis. Blood samples were collected before and
at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 h after dosing on treatment days 5 (after i.v.
ganciclovir) and 15 (after oral valganciclovir). Further sampling to 24 h was
performed in one patient with CLCR values of 10 ml/min (day 5) and 16 ml/min
(day 15). Time deviations were taken into account in the pharmacokinetic anal-
ysis. Blood samples were centrifuged, and serum samples collected and stored at
20°C until analysis. Ganciclovir concentrations were measured by high-perfor-
mance liquid chromatography with UV detection, according to a previously
validated method (22). Linearity was shown over a range of 0.5 to 30 g/ml, with
an intra- and interassay precision of 7.0% and an accuracy of 5%. The lower
limit of quantification was 0.5 g/ml.
Pharmacokinetic data analysis. Pharmacokinetic data were analyzed simulta-
neously using NONMEM (nonlinear mixed-effects modeling) software, version
VI (3). As NONMEM estimated the pharmacokinetic parameters of ganciclovir,
valganciclovir doses were converted to their equivalent ganciclovir content by
multiplying the valganciclovir dose by 0.720 (corresponding to the ratio between
the molecular weights of ganciclovir and valganciclovir).
The modeling process consisted of the following three steps: (i) development
of the base pharmacokinetic model, incorporating interoccasion variability; (ii)
covariate selection; and (iii) model validation. The first-order conditional esti-
mation method with interaction was used throughout the entire model-building
process.
Base population pharmacokinetics model. Models of one and two open com-
partments with first-order absorption were evaluated, as well as models with and
without lag time. The standard lag time models and the transit compartment
models (23) were tested to describe the absorption profile. Interpatient and
interoccasion (16) variability were assumed to have a log-normal distribution.
Additive, proportional, and combined (additive plus proportional) models were
compared to assess the residual error (RE) in drug concentrations. The individ-
ual contribution to the RE was accounted for by including an interpatient
variability term in the RE model when first-order conditional estimation with
interaction was applied (14). This term was implemented as an exponential
model in the RE model (17). The adequacy of the models developed was
evaluated by (i) changes in the minimum objective function value [2log (like-
lihood); MOFV] obtained in NONMEM VI; (ii) the precision of the parameter
estimates; and (iii) goodness-of-fit plots. For nested models, the ratio of the
MOFV is asymptotically chi-square distributed, with degrees of freedom equal to
the difference in the number of model parameters. A significance level of 0.05%
denoted a significant improvement of fit (drop in the MOFV by 7.879) for a
one-parameter difference. Goodness-of-fit was evaluated through plots of typical
population model-predicted or individual Bayesian predicted concentrations ver-
sus observed concentrations or plots of conditional weighted residuals versus
time (12). The Xpose program (13), version 4.0, was used to guide the model-
building process.
Covariate model. The effects of all physiologically reasonable covariates, sum-
marized in Table 2, on model parameters were investigated by plotting empirical
Bayes’s estimates of pharmacokinetic parameters against covariates, using the
generalized additive models procedure (13), and then testing all of them with
NONMEM.
Covariates were first tested univariately in the model and then by the cumu-
lative forward inclusion/backward elimination procedures. Significance levels of
5% (reduction in the MOFV of 3.841 points) and 1% (increase in the MOFV
of 6.635 points) were employed during the forward addition and backward
elimination steps. A decrease of at least 10% in interpatient variability associated
with a specific pharmacokinetic parameter was considered clinically relevant for
the inclusion of that specific covariate. All evaluated relationships between phar-
macokinetic parameters and continuous covariates were centered around the mean.
The covariates were introduced into the base model, in terms of linear relationships.
Because the primary goal of the population pharmacokinetic analysis was to estimate
individual patient ganciclovir pharmacokinetic parameters, the extent of Bayesian
shrinkage was evaluated for each parameter in the final model using the following
formula (15): shrinkage  1  (SDparameter/parameter). In this formula,
SDparameter is the standard deviation of the individual estimates of  (interpatient
variability random effect) for each parameter and parameter is the estimate of the
standard deviation of the estimated population variance. Large values of shrinkage
would be associated with generally poor individual estimates of that parameter.
Model validation. The bootstrap method with replacement was used to assess
the stability of the final model and to construct confidence intervals (CIs) of
pharmacokinetic parameters (10), using PsN-Toolkit version 2.2.6 (19). Two
hundred data sets were reconstructed by resampling from the original data. The
final model was fitted to the replicate data sets, and parameter estimates for each
of the replicate data sets were obtained. The mean values of the parameters
obtained were compared with those estimated from the original data. The lower
and upper limits of the 95% CI for each parameter accounted for its correspond-
ing variability.
Model-based simulations. The simulated values of the area under the concen-
tration-time curve (AUC) following (i) the manufacturer’s dosing strategy taking
into account a body weight of 66.2 kg (mean population value) and (ii) the i.v.
dosing estimated as the target AUC (AUCtarget; 45 g  hr/ml) multiplied by the
population CL (CLpop; predicted by the final population model) or (iii) the oral
dosing estimated as AUCtarget multiplied by the ratio between CLpop and pop-
ulation bioavailability (Fpop; also predicted by the final population model) for 10
TABLE 1. Dosing adjustments based on glomerular filtration rate











a The glomerular filtration rate was calculated using the Cockcroft-Gault formula.





No. of patients 20 10 5 5
Weight (kg) 66.2 (12.9) 65.9 (12.9) 69.6 (10.8) 65.8 (5.5)
Age (yr) 55.7 (11.8) 54.6 (10.3) 53.2 (8.7) 54.4 (17.3)
CLCR (ml/min) 57.0 (25.3) 39.9 (22.9) 75.1 (18.0) 73.2 (5.5)




MMF (yes/no) 16/4 9/1 4/1 5/0
CsA (yes/no) 11/9 3/7 4/1 4/1
TAC (yes/no) 8/12 6/4 1/4 1/4
SRL (yes/no) 1/19 1/9 0/5 0/5
a Data are given as mean (standard deviation) values or counts.
b CsA, cyclosporine; MMF, mycophenolate mofetil; SRL, sirolimus; TAC,
tacrolimus. CLCR was estimated according to the Cockcroft-Gault formula.
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different cutoffs of estimated CLCR values (from 10 to 100 ml/min) were com-
pared.
The simulated AUCs were calculated as dose/individual CL (for i.v. ganciclo-
vir) or as individual F  dose/individual CL (for oral valganciclovir). AUCtarget
was estimated from the mean value of the AUCtarget range proposed by Wiltshire
et al. (27) in SOT patients. The percentages of patients achieving AUCtarget were
estimated in all cases. These simulations evaluated the competence of recom-
mended CLCR-adjusted doses regarding their ability to provide target exposure
values following i.v. ganciclovir and oral valganciclovir treatment.
RESULTS
Patients. Twenty-one Caucasian patients with established
CMV infections undergoing allogeneic SOT (kidney, liver, or
heart) were eligible for inclusion in this study. One patient
(liver transplantation) was excluded from the population phar-
macokinetics analysis because this patient did not complete the
treatment due to pancytopenia.
Baseline demographic and clinical data for all patients, sep-
arated by SOT type, are summarized in Table 2. Dose adjust-
ment according to renal function followed the manufacturer’s
recommendations (Table 1) with the exception of four pa-
tients: one with a CLCR of 27 ml/min who received i.v. ganci-
clovir at 5 mg/kg twice per day; one patient with a CLCR of 55
ml/min who received 900 mg of oral valganciclovir twice per
day; and two patients with CLCR values of 38 and 25 ml/min,
respectively, who received 450 mg of oral valganciclovir twice
per day.
Ganciclovir serum levels. The time profiles of ganciclovir
serum levels following i.v. ganciclovir and oral valganciclovir
administration are displayed in Fig. 1. The smooth line shows
the general trend of the data, and the sampling points ade-
quately define the overall pharmacokinetics profiles of ganci-
clovir after both i.v. and oral administration. The final data set
used for the pharmacokinetics analysis consisted of 382 ganci-
clovir concentrations, 190 from i.v. ganciclovir and 192 from
oral valganciclovir. Only six samples were below the limit of
quantification.
Population pharmacokinetics model. (i) Base population
pharmacokinetics model. The pharmacokinetic disposition of
ganciclovir was best described by a two-compartment open
linear model with first-order absorption process and lag time,
parameterized in terms of total ganciclovir CL, central com-
partment distribution volume (V1), intercompartmental clear-
ance, peripheral compartment distribution volume (V2), first-
order absorption rate constant (ka), F, and lag time. The ka
represents both absorption and hydrolysis of valganciclovir in
the gut wall and liver, before reaching the systemic circulation.
The transit compartment model for modeling the absorption/
metabolism process did not result in further improvement of
the model. The pharmacokinetic parameters estimated from
the base model are listed in Table 3. The logit transformation
was applied to F to restrain its estimate values between 0 and
1. Interpatient variability could be included in CL, V1, ka, and
F. Consideration of interoccasion variability in disposition
pharmacokinetic parameters did not significantly reduce
MOFV (P  0.05). RE was described by a combined error
model where the proportional part estimated in terms of vari-
ance was 0.144 or 37.95% (expressed as coefficient of variation
[CV%]) and the additive part in terms of a standard deviation
was 0.475 g/ml. The inclusion of interpatient variability in the
RE model resulted in a decrease in MOFV of 43.43 points and
was estimated to be 0.099 (expressed as variance) or 31.46%
(expressed as CV%). In addition to resulting in an improve-
ment in individual fits, this led to a marked decrease in the
proportional residual variability of 24.21%.
(ii) Covariate analysis. When covariates were tested univa-
riately, the inclusion of CLCR reduced the MOFV by 33.478
(P  0.001) and contributed to a decrease of interpatient
variability in ganciclovir CL from 68.19% to 32.71%, with
CLCR explaining the 52.03% interpatient variability in CL. The
inclusion of gender and the coadministration of tacrolimus
decreased the MOFV by 9.196 (P  0.01) and 6.354 points
(P  0.05), respectively. The inclusion of body weight in CL
was not statistically significant and explained only 4.74% of the
interpatient variability in this parameter. According to these
results, CLCR was the most influential covariate on CL. Cu-
mulative inclusion of gender in the CLCR covariate model
failed to cause a further significant drop in the MOFV
(1.289, P  0.05). After incorporation of tacrolimus admin-
istration or body weight in the CLCR covariate model, an
increase in the MOFV was observed in both cases. During the
backward elimination, exclusion of any of these covariates, one
at a time, from the CLCR model did not result in a significant
increase in the MOFV. Therefore, a model which regarded
CLCR as the predictor variable of ganciclovir CL was the most
suitable, from both a statistical and clinical viewpoint. In ad-
dition, CLCR explained the majority of interpatient variability
in CL, providing good estimates and significance for all phar-
macokinetic parameters.
Figure 2 shows the goodness-of-fit plots, demonstrating that
the measured and model-predicted concentrations were in
good general agreement for both methods of administration
(i.v. and oral). Neither treatment showed a specific trend for
conditional weighted residuals versus time.
Figure 3 shows superimposed values of the observed, indi-
vidually predicted, and population-predicted ganciclovir serum
concentrations observed in two patients of the population stud-
ied, showing CLCR values of 73 ml/min (median) and 38 ml/
min (low), respectively, after both i.v. ganciclovir and oral
valganciclovir administration. These plots support the fact that
the final model satisfactorily fits the data.
FIG. 1. Ganciclovir serum concentrations versus time postdose fol-
lowing i.v. administration of ganciclovir (left) and oral administration
of valganciclovir (right) in SOT patients. Circles represent observed
ganciclovir concentrations. Solid lines represent the smooth line indi-
cating the general data trend.
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The parameter estimates corresponding to the final model
are also listed in Table 3. Interpatient variability values for CL
were decreased in the final model (interpatient variability of
0.107, expressed as variance, or 32.71%, expressed as CV%)
compared with the values for the base model (interpatient
variability of 0.466, expressed as variance, or 68.26%, ex-
pressed as CV%). Residual variability and interpatient vari-
ability in RE were, in both cases, comparable and estimated





Final model parameter estimate
(relative SE)
Mean (95% CI) bootstrap
resultsb
Pharmacokinetic parameters
CL Liter/h 6.34 (15.93) 7.49 (7.76)  (CLCR/57)
c 7.48 (6.27–8.71)
V1 Liter 32.0 (13.28) 31.90 (9.81) 32.76 (21.93–41.87)
CLD Liter/h 9.65 (18.13) 10.20 (11.86) 9.80 (6.47–13.93)
V2 Liter 31.1 (19.23) 32.0 (17.78) 32.93 (11.57–52.42)
ka h
1 0.971 (18.43) 0.895 (10.77) 0.91 (0.546–1.244)
F 0.760 (6.99) 0.825 (7.07) 0.81 (0.698–0.952)
Lag time h 0.395 (3.67) 0.382 (4.69) 0.38 (0.34–0.42)
Interpatient variability ind:
CL 0.466 (26.39) 0.107 (40.56) 0.106 (0.027–0.187)
V1 0.239 (61.09) 0.227 (63.00) 0.208 (0.045–0.499)
ka 0.478 (39.96) 0.464 (36.85) 0.446 (0.068–0.860)
F 0.026 (48.58) 0.049 (63.90) 0.060 (0.014–0.352)
Residual variability
1 g/ml 0.475 (24.84) 0.465 (15.74) 0.453 (0.235–0.695)
2
2 0.144 (24.58) 0.143 (19.30) 0.145 (0.069–0.217)
	2RE 0.099 (59.84) 0.116 (54.48) 0.134 (0.048–0.28)
a CLD, intercompartmental clearance between central and peripheral compartments; 1, standard deviation of additive component of residual variability; 22,
variance of proportional component of residual variability; 	2RE, interpatient variability in residual error.
b Derived from 200 successful bootstrap sample runs.
c CLCR, creatinine clearance, estimated with the Cockroft-Gault formula (ml/min); 57  mean population CLCR value (ml/min).
d Estimates of interpatient variability are expressed as variance values (	2).
FIG. 2. Goodness-of-fit plots for the population pharmacokinetics model. Upper panels show results for i.v. administration of ganciclovir and
lower panels show results for oral administration of valganciclovir. Ganciclovir concentrations are given in g/ml and time in hours from the start
of the treatment. DV, observed concentrations; PRED, population predictions; IPRED, individual predictions; CWRES, conditional weighted
residuals; dashed line, identity line; solid line, smooth line indicating the general trend of the data.
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with similar precision with respect to the base model (Table 3).
Estimates of the shrinkage for all the pharmacokinetic param-
eters were less than 17%, suggesting that in all the cases, the
individual estimates were reasonably robust.
Figure 4 shows the relationship between ganciclovir expo-
sure predicted by the developed model versus CLCR after i.v.
ganciclovir and oral valganciclovir administration in SOT pa-
tients. These results show a tendency to higher ganciclovir
systemic exposure after valganciclovir compared to that after
i.v. ganciclovir specifically for patients showing CLCR values of
60 ml/min and higher.
Model validation. Table 3 lists results corresponding to the
means and 95% CIs of parameter bootstrap estimates. The
parameter values for the final model generated from the boot-
strap analysis were similar to those of the model developed
using the 20 patients in this study. The percentage of difference
between the final model and mean bootstrap sample data was
lower than 8.5% for all the structural pharmacokinetic and
random-effect parameters, with the exception of interpatient
variability in RE, where the difference was 15.64%. All final
model estimates lie within the 95% CI of the bootstrap values.
These results indicate that the estimates for the fixed and
random effects in the final model are accurate and that the
model is stable.
Model-based simulations. Figure 5 shows the simulated
ganciclovir serum levels and 95% CIs for three estimated
CLCR values (low, 20 ml/min; median, 60 ml/min; and high,
90 ml/min) following the administration of i.v. ganciclovir
and oral valganciclovir according to the adjusted manufac-
turer’s recommended dose (Table 1). A tendency toward
lower model-predicted concentrations with higher CLCR
values, more noticeable after i.v. administration than after
oral administration, is shown.
Table 4 summarizes the average predicted AUC and 95%
CI values using (i) the manufacturer’s recommended dosing
strategy, taking into account a body weight of 66.2 kg (mean
population value), and (ii) the dose adjustment strategy
based on AUCtarget  CLpop (for i.v. administration) or
AUCtarget  (CLpop/Fpop) (for oral administration) for 10
different cutoffs of estimated CLCR values (from 10 to 100
ml/min). The percentages of patients achieving AUCtarget
after each strategy/administration route are also shown. The
dose adjustment strategy (based on AUCtarget in the simu-
lations) resulted in a decreased range of AUCs with respect
to those resulting from the manufacturer’s recommended
strategy for both i.v. and oral administration.
The percentages of patients with AUCs over the target after
FIG. 3. Superimposed values of the observed (DV, open circles),
individually predicted (IPRED, solid line), and population-predicted
(PRED, dashed lines) ganciclovir serum concentrations versus time
postdose in two patients belonging to the population studied, showing
CLCR values of 73 and 38 ml/min, respectively, after both i.v. ganci-
clovir (left) and oral valganciclovir (right) administration.
FIG. 4. Relationship between ganciclovir exposure (AUC) and estimated CLCR in SOT patients after administration of i.v. ganciclovir (left) and
oral valganciclovir (right) according to the manufacturer’s recommended dosage. Vertical lines show dosage adjustments based on CLCR.
Horizontal lines show the AUCtarget value that was considered efficacious.
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the manufacturer’s recommended strategy were in general
higher after oral administration than after i.v. administration
for patients with CLCR values of 20 ml/min and up. The highest
percentages of patients with AUCs over the target were ob-
served at CLCR values of 30 ml/min after both i.v. and oral
administration.
DISCUSSION
Considerable variability exists regarding the pharmacokinet-
ics of ganciclovir following i.v. ganciclovir and oral valganci-
clovir administration in SOT patients. This study was
undertaken to develop a clinically applicable population phar-
macokinetics model to quantify inter- and intrapatient variabil-
ity and to analyze the effects of physiopathological factors on
the pharmacokinetics of ganciclovir, with the aim of explaining
the observed variability.
Therapeutic drug monitoring of ganciclovir after valganci-
clovir administration is not employed in the treatment of SOT
patients infected with CMV. A previous study demonstrated
viremia suppression during prophylaxis with ganciclovir expo-
sure (AUC) of 40 to 50 g  ml/hr (27), suggesting that dose
adjustment to a target exposure value would justify the devel-
opment of a clinically applicable population pharmacokinetics
model. To date, no pharmacokinetics/pharmacodynamics rela-
tionship or target exposure (AUC) values have been estab-
lished for the treatment of CMV disease in infected SOT
patients. The current study represents a first step toward de-
veloping optimal ganciclovir dosing schedules for the treat-
ment of CMV disease on the basis of a pharmacokinetics/
pharmacodynamics relationship.
The pharmacokinetic disposition of ganciclovir was best de-
scribed by a two-compartment open linear model with first-
FIG. 5. Simulated ganciclovir serum concentrations versus time. Mean and 95% CIs obtained from 1,000 simulations of ganciclovir serum
concentration-time profiles after i.v. administration of ganciclovir (left) and oral administration of valganciclovir (right) to patients showing CLCR
values of 20, 60, and 90 ml/min and 66.2 kg of body weight and treated according to the manufacturer’s recommendations. Solid lines show
50th-percentile mean predictions, and dotted lines show 2.5th and 97.5th percentiles.
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order absorption process and elimination from the central
compartment. This corresponds with previous studies of i.v.
ganciclovir (29) and oral valganciclovir in SOT patients (26).
The population pharmacokinetics model obtained in this work
yielded basic pharmacokinetic parameter estimates that were
in agreement with previous results (29).
In the current study, CL of ganciclovir was influenced by
renal function through the estimated CLCR according to the
Cockcroft-Gault formula (5), a result that is expected with a
drug that is excreted unchanged by the kidney (20) and which
has been reported previously (29). Explicitly, the CL of ganci-
clovir was estimated to increase with estimated CLCR. This
supports a CLCR-tiered dosing regimen for ganciclovir/valgan-
ciclovir to ensure similar exposure across the renal function
range in transplant patients.
CLCR was shown to be the most influential covariate; the
estimated CLCR explained most of the interpatient variability
in CL (52.03%). Other covariates tested, statistically justifiable
for the model, including gender or coadministration of tacroli-
mus, were correlated with CLCR. Of note, gender influence
may be confounded because 6 of 10 females were kidney trans-
plant recipients having CLCR values of 38 ml/min, whereas
only 4 of 10 males were kidney transplant recipients and three
of the four had CLCR values of 58 ml/min. Similarly, the
influence of tacrolimus coadministration could be attributed to
the fact that six out of eight patients (75.0%) taking tacrolimus
were kidney transplant recipients and three of these five were
treated with tacrolimus because of an acute rejection episode,
so they had compromised renal function, evidenced by their
estimated CLCR values (lower than 35 ml/min). The results of
the present study indicated that no pharmacokinetic parame-
ters were statistically related to body weight. The influence of
body weight on CL was not statistically significant and ex-
plained only 4% of interpatient variability in CL. Therefore, in
transplant patients, variability due to renal function appeared
to be more relevant than that due to differences in body weight.
In fact, the therapeutic impact of this may be irrelevant since
estimation of CLCR is adjusted by body weight, and hence, this
factor is implicit in dose adjustment using CLCR calculations.
In the present study, the fact that body weight did not sta-
tistically influence CL was inconsistent with the results of a
previous population pharmacokinetics study (29) in which i.v.
ganciclovir (1.2 to 5.0 mg/kg) was given to HIV-positive pa-
tients and kidney transplant patients and which demonstrated
that even when CL was corrected by body weight, CLCR, and
disease process, the interpatient variability associated with
ganciclovir CL was 47.5% (CV%). By comparison, the present
study demonstrated an interpatient variability in ganciclovir
CL of only 32.71% (CV%).
On the other hand, according to that study (29), the ganci-
clovir CL estimated for a 66.2-kg (mean body weight of the
population of the present study) kidney transplant patient with
a CLCR value of 40 ml/min was shown to be 6.43 liter/h [esti-
mated from CL  0.382 
 0.168  body weight  (CLCR/
100)  (1  T)  (1  CMV), where T  0/0.76 for nontrans-
plant/transplant patients and CMV  0/0.41 for HIV-positive
patients shedding CMV into urine/HIV-positive patients with
CMV retinitis], whereas a value of 5.26 liter/h [estimated from
CL  7.49  (CLCR/57)] was given by the model developed in
the present study. These discrepancies could be attributed to
the fact that only 5 of the 53 patients included in the previous
study were kidney transplant patients, and hence, it is possible
that CL values could not be accurately estimated in the kidney
transplant subpopulation.
The results of the present study predicted that typical CL
would range from 1.31 liter/h (for a typical patient with CLCR
of 10 ml/min) to 13.14 liter/h (for a typical patient with CLCR
of 100 ml/min) [both values were estimated from CL 
7.49  (CLCR/57)]. The therapeutic implications of this are that
patients with CLCR values of 100 ml/min would require con-
siderably larger doses (around 10 times) of ganciclovir than
those with CLCR values of 10 ml/min.
TABLE 4. Mean predicted AUC values from different simulated dosing strategies for patients, showing various estimated CLCR values and





Initial dosing according to manufacturer’s instructions
Dose adjustment according tob:
AUCtarget  CLpop AUCtarget  (CLpop/Fpop)





















10 128.74 (67.88–247.90) 100.0 190.35 (71.31–393.63) 98.8 44.70 (23.72–86.93) 49.5 41.15 (14.31–85.07) 41.3
20 62.12 (34.85–123.22) 83.6 93.46 (30.94–196.96) 92.4 44.46 (23.93–84.19) 48.9 40.46 (15.53–90.96) 40.0
30 41.30 (22.67–79.41) 38.9 61.81 (19.87–134.64) 75.4 45.17 (24.70–83.72) 50.7 42.25 (14.62–85.51) 45.0
40 30.88 (17.03–60.83) 13.8 46.46 (14.27–99.48) 52.0 44.35 (24.06–84.90) 48.3 40.19 (13.55–87.60) 40.3
50 25.36 (13.49–47.05) 3.5 38.23 (12.63–78.10) 33.2 44.78 (23.92–86.83) 49.1 40.22 (13.83–82.89) 40.0
60 41.29 (22.13–81.13) 41.0 62.15 (20.39–133.25) 77.2 45.43 (24.41–87.61) 51.6 41.92 (14.37–91.07) 43.0
70 35.67 (18.19–71.31) 22.3 54.41 (16.90–117.60) 65.5 45.35 (23.18–85.84) 50.7 42.52 (13.85–91.53) 44.4
80 32.70 (17.22–61.83) 14.4 48.36 (15.19–105.25) 56.7 45.79 (25.42–82.89) 51.8 42.20 (13.45–83.20) 44.4
90 28.14 (15.47–53.09) 7.3 42.92 (13.50–89.43) 45.0 44.62 (24.15–85.52) 49.1 40.92 (13.77–86.92) 42.1
100 26.55 (13.81–51.58) 3.9 38.13 (9.43–79.44) 35.1 44.62 (24.46–85.50) 49.1 41.79 (14.33–86.84) 43.7
a Mean predicted AUC values, expressed as g  hr/ml, are from different simulated dosing strategies in patients showing estimated CLCR values from 10 to 100
ml/min and body weight of 66.2 kg (mean population value). See Table 1 for dosing adjustments.
b CLpop and Fpop values were estimated from the final model.
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Regarding the other pharmacokinetic parameters estimated
by the final model reported herein, the V1 and V2 values were
consistent with those estimated from results previously re-
ported by Yuen et al. (29) (V1  0.391  body weight and V2 
0.511  body weight; i.e., for a patient of 66.2 kg, V1 was 31.90
liter herein versus 25.88 liter in the study of Yuen et al. and V2
was 32.0 liter versus 33.83 liter, respectively), as was intercom-
partmental clearance (10.20 liter/h versus 13.4 liter/h, respec-
tively).
Both Yuen et al. (29) after administration of i.v. ganciclovir
and Wiltshire et al. (26) after administration of oral ganciclovir
and oral valganciclovir to SOT patients reported that body
weight was statistically significant in V1 and V2; however, no
significant relationship between distribution volumes and body
weight could be demonstrated in the present study.
The ka and lag time parameters estimated in the current
study differed from those reported by Wiltshire et al. (26)
(0.895 versus 0.36 h1 for ka and 0.382 h versus 0.661 h for lag
time, respectively). These differences could be attributed to the
sampling design used in each study. In the present study, the
absorption process was characterized by sampling at 0.5, 1, 1.5,
2, and 3 h postadministration, while in the Wiltshire study (26),
only one sample covered the absorption phase (1 to 3 h). The
absolute F after oral administration of valganciclovir was 0.825
in the present study. To our knowledge, this is the first report
of this parameter in an SOT population infected by CMV.
One of the purposes of this study was to use the model
developed to evaluate the adequacy of the manufacturer’s rec-
ommended CLCR-adjusted doses to prevent under- or overex-
posure to ganciclovir. On the basis of previous work (27),
viremia can be suppressed during prophylaxis with exposures
of 40 to 50 g  hr/ml; hence, in the current study, a target
exposure of 45 g  hr/ml was considered adequate for that
purpose.
Comparison of exposures achieved after the manufacturer’s
recommended initial doses, taking into account a body weight
of 66.2 kg (mean population value in this study), to those after
dose adjustment by AUCtarget using the model developed (Ta-
ble 4) showed that orally administered doses resulted in ade-
quate exposures in all cases, with the exception of patients with
CLCR values under 30 ml/min, in which case overexposure
occurred. Actually, mean AUC values of 94.46 g  hr/ml
(CLCR  20 ml/min) and 190.35 g  hr/ml (CLCR  10 ml/
min) were found with the 92.4% and 98.8%, respectively, of
patients showing exposure values higher than 45 g  hr/ml.
After i.v. administration, a tendency to underexposure for pa-
tients with CLCR values over 80 ml/min (mean AUC values
were 28.14 g  hr/ml for patients with a CLCR of 90 ml/min
and 26.55 g  hr/ml for those with a CLCR of 100 ml/min) and
overexposure for patients with CLCR values under 30 ml/min
was observed (mean AUC values were 62.12 g  hr/ml for
patients with a CLCR of 20 ml/min and 128.74 g  hr/ml for
those with a CLCR of 10 ml/min). Patients with CLCR values of
50 ml/min were specifically underdosed after i.v. administra-
tion (mean AUC values were 25.36 g  hr/ml, and only 3.5%
of patients achieved an exposure higher than 45 g  hr/ml).
These results are also graphically displayed in Fig. 4 and are in
agreement with the percentages of patients achieving exposure
values over 45 g  hr/ml for each CLCR cutoff value (Table 4).
Dose adjustment by the model developed in this study pro-
vided mean AUC values closer to the target of 45 g  hr/ml in
all cases. Moreover, the percentages of patients achieving ex-
posures higher than 45 g  hr/ml ranged from 40 to 50%,
which is more in line with the percentages that should be
expected.
The results presented here also indicate that our model
could provide initial dose optimization based on CLCR values
and the target exposure (AUC) required to achieve efficacy, as
well as further therapeutic drug monitoring, specifically for
those patients in whom changes in renal function can occur
throughout the treatment period.
In conclusion, adaptive dosing following the start of the
treatment was feasible in the population studied, since they
received repeated doses of ganciclovir/valganciclovir. An ap-
proach allowing modification of the ganciclovir/valganciclovir
dose to achieve a target plasma exposure from the start of the
treatment is likely to improve outcome in SOT patients in-
fected by CMV. Studies with a larger number of patients would
be necessary to confirm the optimum dosage regimen after
both i.v. and oral administration. Hence, the results from this
study might assist the optimization of initial dosing regimens
aimed at achieving AUCtarget from the start of the treatment.
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